New Echocardiographic Parameters for Assessment of Longitudinal Left Ventricular Function (LAX)

This study is currently recruiting participants. (see Contacts and Locations)
Verified August 2013 by Heidelberg University
Sponsor:
Information provided by (Responsible Party):
Derliz Mereles, University of Heidelberg
ClinicalTrials.gov Identifier:
NCT01275963
First received: January 12, 2011
Last updated: August 25, 2013
Last verified: August 2013

January 12, 2011
August 25, 2013
January 2011
December 2014   (final data collection date for primary outcome measure)
left ventricular longitudinal systolic strain (LV-LSS) in all patients [ Time Frame: 2 years ] [ Designated as safety issue: No ]
left ventricular longitudinal systolic strain (LV-LSS) is measured in all patients by speckle tracking strain imaging
left ventricular longitudinal systolic strain (LV-LSS) [ Time Frame: 2 years ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT01275963 on ClinicalTrials.gov Archive Site
  • mitral annular plane systolic excursion (MAPSE) in all patients [ Time Frame: 2 years ] [ Designated as safety issue: No ]
    MAPSE is measured by M-Mode echocardiography
  • mitral annular systolic velocity (MASV) in all patients [ Time Frame: 2 years ] [ Designated as safety issue: No ]
    MASV is derived from tissue doppler
  • diastolic left ventricular function in all patients [ Time Frame: 2 years ] [ Designated as safety issue: No ]
    Diastolic function is assesed by mitral inflow, mitral annulus velocity, pulmonary vein flow and velocity of flow progression.
  • pulmonary artery systolic pressure (PASP) in all patients [ Time Frame: 2 years ] [ Designated as safety issue: No ]
    PASP is derived from Tricuspid valve regurgitation velocity
  • left ventricular ejection fraction (LVEF) in all patients [ Time Frame: 2 years ] [ Designated as safety issue: No ]
    EF is measured by modified Simpson's rule (biplane)
  • mitral annular plane systolic excursion (MAPSE) [ Time Frame: 2 years ] [ Designated as safety issue: No ]
  • mitral annular systolic velocity (MASV) [ Time Frame: 2 years ] [ Designated as safety issue: No ]
  • diastolic left ventricular function [ Time Frame: 2 years ] [ Designated as safety issue: No ]
    (assesed by mitral inflow, mitral annulus velocity, pulmonary vein flow and velocity of flow progression)
  • pulmonary artery systolic pressure (PASP) [ Time Frame: 2 years ] [ Designated as safety issue: No ]
  • left ventricular ejection fraction (LVEF) [ Time Frame: 2 years ] [ Designated as safety issue: No ]
    (by modified Simpson's rule)
Not Provided
Not Provided
 
New Echocardiographic Parameters for Assessment of Longitudinal Left Ventricular Function
New Echocardiographic Parameters for Assessment of Longitudinal Left Ventricular Function

Assessment of left ventricular systolic function is the most frequent indication for routine echocardiography. Qualitative eyeball method and biplane modified Simpson's rule, both measuring radial ventricular function, are the currently recommended methods to meet this challenge. Due to the complexity of the myocardial architecture, global left ventricular function also has longitudinal and torsional components.

The aim of this study is to evaluate new echocardiographic parameters for longitudinal left ventricular function. A special focus is set on strain imaging by speckle tracking, which is a relatively new technique. Patients with different cardiac pathologies (e. g. dilated cardiomyopathy, coronary artery disease, diastolic dysfunction) will be included and compared to healthy individuals.

Not Provided
Observational
Observational Model: Case Control
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample

Healthy individuals and patients with various cardiac pathologies, who undergo routine echocardiography at our department

Cardiovascular Pathology
Not Provided
  • Control
    Healthy individuals without structural heart disease
  • CAD
    Patients with coronary artery disease
  • DCM
    Participants with dilated cardiomyopathy
  • HNCM
    Patients with hypertrophic non-obstructive cardiomyopathy
  • HOCM
    Patients with hypertrophic obstructive cardiomyopathy
  • RCM
    Patients with restrictive cardiomyopathy
  • Amyloidosis
    Patients with cardiac manifestation of amyloidosis
  • HFPEF
    Patients with heart failure with preserved ejection fraction (diastolic heart failure)
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
160
Not Provided
December 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • persons of 18 years and older who receive a transthoracic echocardiography at our department
  • written consent

Exclusion Criteria:

  • permanent pacemaker rhythm
  • moderate/severe valvular heart disease
Both
18 Years and older
Yes
Contact: Derliz Mereles, M.D. +49622156 ext 8852 derliz.mereles@med.uni-heidelberg.de
Contact: Matthias Aurich, M.D. +49622156 ext 38893 matthias.aurich@med.uni-heidelberg.de
Germany
 
NCT01275963
S-401/2010
No
Derliz Mereles, University of Heidelberg
Heidelberg University
Not Provided
Principal Investigator: Matthias Aurich, M.D. Heidelberg University
Principal Investigator: Derliz Mereles, M.D. Heidelberg University
Heidelberg University
August 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP